Riggan Kirsten A, Michie Marsha, Allyse Megan
Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.
Department of Bioethics, Case Western Reserve University, Cleveland, Ohio, USA.
AJOB Empir Bioeth. 2025 Jan-Mar;16(1):10-21. doi: 10.1080/23294515.2024.2388533. Epub 2024 Aug 7.
Potential clinical interventions to mitigate or eliminate symptoms of Down syndrome (DS) continue to be an active area of pre-clinical and clinical research. However, views of members of the DS community have yet to be fully explored.
We conducted a survey with parents/caregivers of people with DS ( = 532) to explore interest in potential therapeutic approaches during fetal development or childhood that may improve neurocognition and modulate the DS phenotype. We qualitatively analyzed open-ended responses.
Some respondents rejected the development of therapies for DS categorically as being fundamentally ableist and promoting the erasure of diverse individuals. Many reflected tensions between the desire to improve quality of life and an aversion to erasure of a child's personality.
Findings suggest that views on identity, personality, and disability may influence the acceptance of new interventions, especially if they are thought to mitigate positive attributes of the phenotype or negatively influence social acceptance of people with DS.
减轻或消除唐氏综合征(DS)症状的潜在临床干预措施仍是临床前和临床研究的一个活跃领域。然而,唐氏综合征患者群体成员的观点尚未得到充分探讨。
我们对唐氏综合征患者的父母/照顾者(n = 532)进行了一项调查,以探讨他们对胎儿发育或儿童期可能改善神经认知并调节唐氏综合征表型的潜在治疗方法的兴趣。我们对开放式回答进行了定性分析。
一些受访者坚决拒绝开发针对唐氏综合征的疗法,认为这本质上是能力主义的,会促使消除不同个体。许多人反映出在改善生活质量的愿望与不愿消除孩子个性之间的矛盾。
研究结果表明,对身份、个性和残疾的看法可能会影响对新干预措施的接受程度,特别是如果这些干预措施被认为会减轻表型的积极特征或对唐氏综合征患者的社会接受度产生负面影响。